Anticholinergic vs Long-Acting β-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma

Authors:

Abstract
National treatment recommendations suggest increasing inhaled corticosteroid (ICS) dose or adding a long-acting β-agonist (LABA) to asthma patients with poor asthma control on low-dose ICS.1,2 However, asthma experts and the US Food and Drug Administration have questioned the safety of LABA therapy,3-5 noting possible increases in serious events, including hospitalizations and death. Data suggest that LABA risks, if they exist, may disproportionately affect black populations6 and that black individuals may not benefit from LABAs to the same degree as individuals of other races.7-9 Some studies have suggested that allelic variation at the Arg16Gly locus of the β2-adrenergic receptor (ADRB2 [NCBI Entrez Gene 109690]) gene may be associated with increased rates of adverse outcomes when LABAs are used for asthma,10-12 especially among black patients.13

This publication has 18 references indexed in Scilit: